Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MMP9 | P14780 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21272993 | 1.00 | USP2 (0.48) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL795742 | 1.00 | USP2 (0.48) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL7618433 | 0.88 | USP2 (0.55) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL5990289 | 0.83 | CA1 (0.59) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL4204052 | 0.82 | CA1 (0.43) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL4204044 | 0.82 | CA1 (0.43) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL5636350 | 0.82 | USP2 (0.48) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL8064670 | 0.82 | USP2 (0.48) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL25244523 | 0.80 | CA1 (0.41) | USP2ALDH1A1TSHRKDM4ELMNA | |
| SCHEMBL6653864 | 0.80 | ALDH1A1 (0.46) | USP2ALDH1A1TSHRKDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745134-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | Jiangsu Yahong Meditech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12234245-B2 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | GENENTECH, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| WO-2025016323-A1 | PROTEIN ARGINASE METHYLTRANSFERASE-5 INHIBITOR AND MEDICAL USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2025-01-23 | — | — | WO | disclosed |
| EP-4026832-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Almac Discovery Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3823974-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2021-05-26 | — | — | EP | disclosed |
| US-10766903-B2 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | ALMAC DISCOVERY LIMITED (GB) | 2020-09-08 | — | — | US | disclosed |
| WO-2020018975-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | GENENTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | GENETECH, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | USP7, USP5, UBA7 | USP2 10/4885ALDH1A1 1201/4885TSHR 4422/4885 |
| US-20250115618-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | USP2 1198/4885ALDH1A1 1225/4885TSHR 4570/4885 |
| US-10766903-B2 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | USP7, USP5, UBA7 | USP2 10/4885ALDH1A1 1201/4885TSHR 4422/4885 |
| US-20210253596-A1 | SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1A, IL18, IL1B | USP2 1198/4885ALDH1A1 1225/4885TSHR 4570/4885 |
| US-12234245-B2 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity | IL1A, IL18, IL1B | USP2 1198/4885ALDH1A1 1225/4885TSHR 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.